Estrogen Receptor Antagonist [EPC]

15343 reported adverse events

Drugs of this class: FULVESTRANT

These side effects are most commonly reported by patients taking drugs of the Estrogen Receptor Antagonist [EPC] class:

# Side effect Count
0 FATIGUE 1970
1 MALIGNANT NEOPLASM PROGRESSION 1926
2 NAUSEA 1339
3 NEOPLASM PROGRESSION 1186
4 NEUTROPENIA 1064
5 DEATH 1050
6 WHITE BLOOD CELL COUNT DECREASED 1038
7 DIARRHOEA 1021
8 METASTASES TO BONE 1010
9 ASTHENIA 852
See all common reactions for Estrogen Receptor Antagonist [EPC]

Drugs of the Estrogen Receptor Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PIK3CA-ACTIVATED MUTATION 45 0.5114
1 INFUSION SITE COLDNESS 23 0.3898
2 CARBOHYDRATE ANTIGEN 27.29 INCREASED 27 0.3068
3 PSEUDOCIRRHOSIS 55 0.2989
4 HORMONE RECEPTOR POSITIVE BREAST CANCER 11 0.2895
5 CARBOHYDRATE ANTIGEN 15-3 INCREASED 84 0.2561
6 BRAF GENE MUTATION 9 0.1915
7 METASTASES TO SPINAL CORD 13 0.1831
8 METASTASES TO EYE 24 0.1727
9 METASTASES TO CHEST WALL 34 0.1667
See all enriched reactions for Estrogen Receptor Antagonist [EPC]